| Literature DB >> 35956991 |
Farah Diab1, Hawraa Zbeeb1, Francesca Baldini2, Piero Portincasa3, Mohamad Khalil3, Laura Vergani1.
Abstract
Numerous plants, plant extracts, and plant-derived compounds are being explored for their beneficial effects against overweight and liver diseases. Obesity is associated with the increased prevalence of non-alcoholic fatty liver disease (NAFLD), becoming the most common liver disease in Western countries. Obesity and NAFLD are closely associated with many other metabolic alternations such as insulin resistance, diabetes mellitus, and cardiovascular diseases. Many herbs of the Lamiaceae family are widely employed as food and spices in the Mediterranean area, but also in folk medicine, and their use for the management of metabolic disorders is well documented. Hereby, we summarized the scientific results of the medicinal and nutraceutical potential of plants from the Lamiaceae family for prevention and mitigation of overweight and fatty liver. The evidence indicates that Lamiaceae plants may be a cost-effective source of nutraceuticals and/or phytochemicals to be used in the management of metabolic-related conditions such as obesity and NAFLD. PubMed, Google Scholar, Scopus, and SciFinder were accessed to collect data on traditional medicinal plants, compounds derived from plants, their reported anti-obesity mechanisms, and therapeutic targets.Entities:
Keywords: Lamiaceae; medicinal plants; non-alcoholic fatty liver disease (NAFLD); nutraceutics; obesity; phytochemicals
Mesh:
Year: 2022 PMID: 35956991 PMCID: PMC9370348 DOI: 10.3390/molecules27155043
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Geographical representation of the worldwide distribution of different Lamiaceae plants.
Figure 2Chemical structures of the most abundant and common bioactive compounds found in Lamiaceae plant species (ChemDraw2020 software, PerkinElmer Informatics, Waltham, MA, USA). Phenolic acids: Chlorogenic acid, Caffeic acid, Rosmarinic acid; Phenylpropanoid: Eugenol; Terpenoids: Camphor; Monoterpenoids: Carvacrol, Thymol; Diterpenoids: Abietane; and Flavonoids: Quercetin, Luteolin, Apigenin, Kaempferol.
An overview summary on the most abundant bioactive compounds in each species, its applications, and the number of citations for each.
| List of Plants | Most Abundant Bioactive Compounds | Applications |
|---|---|---|
| Diterpenoids: abietane and labdane | Folk medicine | |
| Caffeic acid, chlorogenic acid, and quercetin | Uses in food, folk medicine, primary cosmetics, and a part of religious rituals | |
|
| Thymol, carvacrol apigenin, luteolin, thymusin, rosmarinic, and caffeic acid and derivatives | Traditional phytomedicine, food, food additive, spicy, and herbal tea |
| Carnosic acid, rosmarinic acid, camphor, caffeic acid, ursolic acid, betulinic acid, and carnosol | Traditional phytomedicine, food additives, and herbal tea | |
|
| Menthol, luteolin, rosmarinic acid, Kaempferol, and hesperidin | Traditional phytomedicine, food, food additive, spicy, herbal tea |
| Rosmarinic acid, geranial, neral, luteolin, naringin, hesperidin, and caffeic acid and derivatives | Traditional phytomedicine, food flavoring, and herbal tea | |
| Chlorogenic acid, caffeic acid, and quercetin | Herbal medicine | |
| Carvacrol and rosmarinic acid | Culinary ingredient: in salad and tea infusion | |
| Rosmarinic acid | Folk medicine | |
| Rosmarinic acid and derivatives | Traditional phytomedicine | |
| Flavonoid: Baicalein, wogonoside, and wogonin | Traditional phytomedicine | |
|
| Eugenol, rosmarinic acid, apigenin, luteolin, β-sitosterol, and carnosic acid | Traditional phytomedicine, food additive, spicy, and fragrance agent |
| Caffeic acid | Traditional phytomedicine, gelatin-type dessert, and herbal beverage | |
| Marrubin and premarrubin | Traditional phytomedicine |
Main in vitro and in vivo (animal models) studies with the different species of the Lamiaceae family.
| Plants | Models | Treated Disorders | Proposed Mechanisms | Ref. | |
|---|---|---|---|---|---|
| In vivo | Male Wistar rats | Diabetes | ↑Insulin secretion | [ | |
| In vitro | 3T3-L1 pre-adipocyte cell line | Diabetes | ↓Blood GLU, TNF-α, KC/GRO, and IL-12 | [ | |
| In vivo | Male Wistar rats | Diabetes | Improvement in serum creatinine and UA concentrations | [ | |
| In vivo | Female Balb/c mice and male Wistar rats | Diabetes | ↓Gluconeogenesis | [ | |
| In vivo | Female Wistar rats | Hyperlipidemia | ↓plasma Chol, HDL-Chol, LDL-Chol, TG, total lipids, and VLDL | [ | |
| In vivo | Male Wistar rats | Dyslipidemia | Prevention of cholestasis elevation (AP, GGTP, and TB) | [ | |
| In vivo | Adult female Wistar rats | Hyperlipidemia | ↑SOD and CAT activities | [ | |
| In vivo | Male Wistar rats | Obesity | Improvements in insulin sensitivity and plasma lipid profile (TG, FFA, & Chol) | [ | |
| In vivo | Wistar rats SRD-fed | Dyslipidemia | ↓Body weight | [ | |
| In vivo | Wistar rats SRD-fed | Dyslipidemia | ↓Adipocyte hypertrophy, cell volume, and size distribution | [ | |
| In vivo | Wistar rats SRD-fed | Dyslipidemia | ↓Systolic blood pressure | [ | |
| In vivo | Sodium nitrite-treated mice | Liver damage | ↓ AST, ALT, MDA, IL-1β, IL-6, TNF-α, | [ | |
| In vivo | Gentamicin-treated rats | Liver damage | ↓ AST, ALT, bilirubin, total lipids, ROS | [ | |
| In vivo | Streptozotocin-treated rats | T2DM | ↓Blood GLU and weight | [ | |
| In vivo | Alloxan-induced Diabetic Mice | Diabetes | ↓Fasting blood GLU | [ | |
| In vivo | Streptozotocin/nicotinamide-induced type 2 diabetic rats | Diabetes | ↓Blood GLU | [ | |
| In vitro | Hela cells | Oxidative stress | ↓ROS | [ | |
| In vitro | HepG2 cells | Obesity | ↑AMPK, ACC, LDLR and PPARα | [ | |
| In vitro | Preadipocytes | Obesity | ↓TG | [ | |
| In vitro | L6 myotubes | Insulin resistance | Restored insulin-simulated GLU uptake | [ | |
| In vivo | Male Wistar rats | Oxidative stress | ↓TBARS, H2O2 | [ | |
| In vivo | Rats | Liver toxicity | ↑SOD, CAT and GPx activities | [ | |
| In vivo | Rats | Hypercholesterolemia | ↓Chol, HDL and TBARS | [ | |
| In vivo | Mice | Inflammation | ↓ COX2, PGE-2, IL- 1b, MMP2 and NO | [ | |
| In vivo | Nicotine-induced liver damage in Wistar rats | Liver damage | ↓AST, ALP, ALT, LDH and MDA | [ | |
| In vivo | Rats | Liver damage | ↓ALT, AST, ALP, and LDH | [ | |
| In vivo | Rats | Liver damage | ↓p53 | [ | |
| In vivo | Rats | Liver damage | ↓ALT, AST, ALP, and LDH | [ | |
| In vivo | HFD-fed mice | NAFLD | ↓blood GLU, insulin, leptin and TG | [ | |
| In vitro | HUVECs | Oxidative stress | ↑ cell viability | [ | |
| In vitro | HUVECs | Obesity | ↓ body weight gain, adipose tissue mass and adipocyte size | [ | |
| In vitro | HepG2 cells | Obesity | ↓ body weight gain | [ | |
| In vitro | HepG2 cells | NASH | ↑ SOD, CAT and GPx activities | [ | |
| In vivo | Mice | Oxidative stress | ↓Mn-induced TBARS levels | [ | |
| In vivo | Rats | Diabetes | ↓ weight, hyper-glycemia, hypo-insulinemia and hepatic lipid accumulation | [ | |
| In vitro | INS-1E cells | Diabetes | ↑ Insulin secretion | [ | |
| In vivo | C57BL/6 mice | Hypercholesterolemia | ↓ Plasma cholesterol | [ | |
| In vivo | C57BL/6 mice | Obesity | ↓ Serum TG, TC, and LDL-Chol | [ | |
| In vitro | Rat hepatocytes FaO cells | Steatosis | ↓ Hepatic lipid accumulation | [ | |
| In vivo | HFD-fed mice | NAFLD | ↓ TC, LDL-Chol, TG, and MDA | [ | |
| In vivo | Paracetamol-insulted rats | Liver damage | ↑ SOD and GPx | [ | |
| In vivo | C57BL/6 mice | Hyperlipidemia | ↓ Body weight, TG, TC, and LDL-Chol | [ | |
| In vivo | Sprague Dawley rats | Diabetes | ↑ GLP-1 and ghrelin levels | [ | |
| In vitro | HepG2 cells | NAFLD | ↓Intracellular lipid accumulation | [ | |
| In vitro | Human umbilical vein endothelial cells (HUVEC) | High glucose- induced Vascular inflammation | ↓ cell adhesion molecules (CAMs) | [ | |
| In vivo | Mice | Liver injury | ↓ serum ALT, AST, ALP, TG, total Chol, and total bilirubin | [ | |
| In vitro | HepG2 cells | NAFLD | ↓TG and Chol | [ | |
| In vivo | Type 2 diabetic db/db mice | Obesity | ↓ weight gain, TG, ALT and hyperinsulinemia | [ | |
| In vivo | Mice | Insulin-resistance | ↓Fasting and postprandial GLU, fasting insulin, HOMA-IR, TG and LDL-Chol | [ | |
| In vivo | Ovariectomized rats | Obesity | ↓Body weight | [ | |
| In vivo | Rats | Dyslipidaemia | ↓Lipogenesis | [ | |
| In vivo | Rats | Hyperlipidemia | ↓Lipid accumulation | [ | |
| In vivo | Rats | Diabetes | ↓Glucose | [ | |
| In vitro | RAW 264.7 cells | Immune deficiency | ↑SOD, CAT and GPx activities | [ | |
| In vivo | Rats | Diabetes mellitus | inhibited fresh egg albumin-induced paw edema and hypoglycemic effects in rats | [ | |
| In vitro | INS-1 cells | Hyperglycemia | ↑ GLUT2 expression | [ | |
| In vitro | 3T3, Chang, C2C12, INS-1 | Obesity | ↑ PPAR | [ | |
↓, significantly decreased; ↑, significantly increased.
Main clinical controlled trials on the intake of Lamiaceae plant species.
| Plants | Sample Size | Gender (Age) | Participants | Format, Dose | Duration of Study | Action | Ref. |
|---|---|---|---|---|---|---|---|
| Men and women | T2DM patients | tablets (150 mg extract/three times/day) | 90 days | ↓2hpp blood sugar and Chol | [ | ||
| Men and women | Hyperlipidemic T2DM patients | extract capsules (500 mg/8 h) | 90 days | ↓GLU, HbA1c, total Chol, TG, and LDL-Chol | [ | ||
| Women (40–50 years) | Diabetic patients | Tea, (300 mL/twice a day) | 28 days | ↓Plasma LDL-Chol and total Chol | [ | ||
| Men and women | NAFLD patients | Milled chia (25 g/day) | 70 days | ↓Body weight, total Chol, FFA, and non-HDL-Chol | [ | ||
| Men and women (35–75 years) | Overweight and obese patients with T2DM | ground chia (30 g/1000 kcal daily) | 180 days | Weight loss | [ | ||
| Men and women (64 ± 8 years) | T2DM patients | 37 ± 4 g/day | 84 days | ↓SBP | [ | ||
| Men and women (21–65 years) | T2DM patients | Chia seeds (40 g/day) | 84 days | ↓SBP | [ | ||
| Men and women (46–67 years) | Hypercholesterolemic patients | 25 mL/day | 3 weeks | ↓ox-LDL | [ | ||
| Men and women (46–64 years) | Hypercholesterolemic patients | 25 mL/day | 3 weeks | ↑expression of key cholesterol efflux regulators | [ | ||
| Men and women (mean age 56) | Type 2 diabetes | Tea, 2 g/L/day | 90 days | ↓ body mass index | [ | ||
| Men and women (40–65 years) | Blood hypertension patients | 300 mL/day | 16 weeks | ↓Systolic (SBP), diastolic blood pressures (DBP), mean arterial blood pressures (MAP) | [ | ||
| Men and women (25–65 years) | Hyperlipidemic patients | Two capsules (500 mg each) after meals, 3 times/day | 2 months | ↓ LDL | [ | ||
| Men and women (20–65 years) | T2DM patients | two capsules (each 350 mg)/day | 12 weeks | ↓HbA1c, TG and hs-CRP | [ | ||
| Men (20–40 years) | overweight | HC meal + 0.5 or 1 g of extract | 4 h | ↓MDA and serum TG | [ |
↓, significantly decreased; ↑, significantly increased.
Figure 3A Group of Lamiaceae plants (Available online: www.theplantlist.org, accessed on 5 August 2022) included in the review. (A): Salvia officinalis L., (B): Salvia hispanica L., (C): Thymbra capitata (L.) Cav., (D): Thymus saturejoides Coss., (E): Rosmarinus officinalis L., (F): Mentha spicata L., (G): Melissa officinalis L., (H): Leonurus sibiricus L., (I): Thymbra spicata L., (J): Orthosiphon aristatus (Blume) Miq., (K): Lycopus lucidus Turcz. ex Benth., (L): Scutellaria baicalensis Georgi., (M): Ocimum species, (N): Mesona chinensis Benth., (O): Leonotis leonurus (L.) R.Br.
Figure 4A schematic cartoon showing the main complications resulting from overnutrition and obesity: primarily liver steatosis and the mechanistic road for its progression, displaying also the potency of Lamiaceae plants in treating these complications in several experimental models (in vitro, in vivo, and clinical trials).